Bold strategies are required to remedy frequent stock-outs and supply interruptions By Lindsay McKenna Drug shortages, especially of tuberculosis (TB) drugs, have become increasingly common in the United States. Over the past year alone, the U.S. Centers for Disease Control…
Funding cuts and shifting budgetary priorities threaten tuberculosis gains By Coco Jervis The United States is losing ground in its fight against the tuberculosis (TB) epidemic within its own borders. Sequestration and shifting priorities of Congress and the Obama administration…
By Mark Harrington In death one can’t be vocal or witness time and motion and physical events with breath, one can’t make change. Abstract ideas of energy dispersing, some ethical ocean crawls through a funnel of stars, outlines of the…
Health insurance co-payment (co-pay) programs and patient drug assistance programs (PAPs) are critical services for thousands of U.S. residents with HIV and/or viral hepatitis who face out-of-pocket expenses associated with their treatment. The Fair Pricing Coalition (FPC) has negotiated co-pay…
Simultaneous, not sequential, evaluations of novel drug regimens needed to speed TB treatment research By Lindsay McKenna An example of a multi-arm multi-stage (MAMS) phase II trial design. At the first interim analysis, novel regimen 2 is considered to lack…
Rifapentine’s manufacturer helps to advance TB research while stalling access By Erica Lessem Sanofi-Aventis, manufacturer of the tuberculosis (TB) drug rifapentine (Priftin), can be credited for aiding research efforts to shorten and simplify treatment dosing for TB. However, the company’s…
Immunologic nonresponders face increased risk of illness, but lack therapeutic options By Richard Jefferys A subset of people on antiretroviral therapy (ART) experience limited or no recovery of CD4 T-cell counts despite achieving and maintaining undetectable viral loads. Various terms…
The push for affordable HIV treatment doesn’t end with patent expirations By Tim Horn Expiry of guidelines-preferred and -alternative first-line ARTs The United States is on course for some much-needed economic relief from the crippling cost of HIV treatment, with…
The discovery of HAART and the push for evidence-based HIV treatment By Mark Harrington This is the third in a series looking back at the first two decades of TAG’s work to speed up AIDS research. In Part I: TAG’s…